POLYCYSTIC OVARY SYNDROME (PCOS) TREATMENT MARKET ANALYSIS

Polycystic Ovary Syndrome (PCOS) Treatment Market, By Drug Class (Oral contraceptives, Insulin Sensitizing Agents, Anti-Depressants, Ornithine Decarboxylase Inhibitors, Aromatase Inhibitors & SERMs and Diuretics), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

Published In : Apr 2023
Code : CMI1589
Pages :177
Formats :
Excel and PDF
Industry : Pharmaceutical

Regional Analysis

Global Polycystic Ovary Syndrome (PCOS) Treatment Market- Regional Analysis

Among regions, North America is estimated to hold a dominant position in the global polycystic ovary syndrome (PCOS) treatment market over the forecast period due to the increasing prevalence of polycystic ovary syndrome. For instance, in December 2022, The Centers for Disease Control and Prevention, the national public health agency of the U.S., published a data, according to which polycystic ovary syndrome (PCOS) is one of the common causes of female infertility, which affect 6% to 12% (as many as 5 million) of the U.S. women of reproductive age.

North America: U.S. and Canada
Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
Middle East: GCC Countries, Israel, and Rest of Middle East
Africa: South Africa, North Africa, and Central Africa